EGFR and cancer: Knowledge of the role of the EGFR in malignant tumors has advanced enormously over the last 20 years, and several therapeutic drugs such as tyrosine kinase inhibitors and anti-EGFR monoclonal antibodies have been registered for epithelial-derived tumors [8–10].